ClinicalTrials.gov
ClinicalTrials.gov Menu

Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00916123
Recruitment Status : Active, not recruiting
First Posted : June 9, 2009
Last Update Posted : August 15, 2018
Sponsor:
Information provided by (Responsible Party):
Weill Medical College of Cornell University

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : December 2020
  Estimated Study Completion Date : December 2021